Key Takeaway: Innate Pharma has confirmed that its strategic partnership with Sobi is now effective after fulfilling necessary closing conditions, including antitrust waiting periods. This partnership, initially announced on August 10, 2026, involves the licensing of lacutamab for T-cell lymphoma. The transaction includes a significant financial component of USD 75 million.
Market Sentiment Analysis
POSITIVE FACTORS
Strategic partnership with Sobi is now effective.
Completion of closing conditions enhances collaboration.
Licensing of lacutamab in T-cell lymphoma shows promise.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
7.6%
average across 4 past catalysts
Lead asset
IPH2101
Phase 2 · Smoldering Multiple Myeloma
Full Press Release Details
MARSEILLE, France--(BUSINESS WIRE)---- $IPH #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the previously announced strategic partnership with Sobi is now effective following the expiration of applicable antitrust waiting periods and completion of other conditions. As announced on August 10, 2026, Innate Pharma entered a strategic partnership with Sobi to license lacutamab in T-cell lymphoma. Transaction closing triggers the USD 75
Frequently Asked Questions
What partnership did Innate Pharma announce?
Innate Pharma announced a strategic partnership with Sobi.
What is the focus of the partnership?
The partnership focuses on licensing lacutamab for T-cell lymphoma.
When was the partnership initially announced?
The partnership was initially announced on August 10, 2026.
What conditions were completed for the partnership?
The partnership became effective after antitrust waiting periods and other conditions were fulfilled.